Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Head and Neck Cancer

Free Subscription 21.01.2019 1 Ann Surg 4 Anticancer Res 4 BMC Cancer 1 Cancer 1 Cancer Res 2 Clin Nucl Med 4 Dis Esophagus 4 Head Neck 1 Histopathology 1 Int J Cancer 4 Laryngoscope

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Surg

1. VAN PUTTEN M, Koeter M, van Laarhoven HWM, Lemmens VEPP, et al
   Hospital of Diagnosis Influences the Probability of Receiving Curative Treatment for Esophageal Cancer.
   Ann Surg. 2018;267:303-310.
   PubMed     Text format     Abstract available
   
   

   
   Anticancer Res

2. HAMADA J, Konishi H, Shiozaki A, Fujiwara H, et al
   Management of Pleural Effusion After Mediastinoscopic Radical Esophagectomy.
   Anticancer Res. 2018;38:6919-6925.
   PubMed     Text format     Abstract available
   
   
3. FUSHIMI A, Takeyama H, Manome Y
   Effect of Heparin-Protamine Treatment on Thyroid Cancer Cell Lines.
   Anticancer Res. 2018;38:6759-6762.
   PubMed     Text format     Abstract available
   
   
4. MURATA T, Kutsuna T, Kurohara K, Shimizu K, et al
   Evaluation of a New Hydroxyapatite Nanoparticle as a Drug Delivery System to Oral Squamous Cell Carcinoma Cells.
   Anticancer Res. 2018;38:6715-6720.
   PubMed     Text format     Abstract available
   
   
5. MASSIMINO M, Tirro E, Stella S, Frasca F, et al
   Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells.
   Anticancer Res. 2018;38:6653-6662.
   PubMed     Text format     Abstract available
   
   

   
   BMC Cancer

6. YOU GR, Cheng AJ, Lee LY, Huang YC, et al
   Prognostic signature associated with radioresistance in head and neck cancer via transcriptomic and bioinformatic analyses.
   BMC Cancer. 2019;19:64.
   PubMed     Text format     Abstract available
   
   
7. ZHANG Y, Chen Y, Liu Z, Lai R, et al
   ERK is a negative feedback regulator for IFN-gamma/STAT1 signaling by promoting STAT1 ubiquitination.
   BMC Cancer. 2018;18:613.
   PubMed     Text format     Abstract available
   
   
8. OFFMAN J, Muldrew B, O'Donovan M, Debiram-Beecham I, et al
   Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
   BMC Cancer. 2018;18:784.
   PubMed     Text format     Abstract available
   
   
9. BAHIG H, Aubin F, Stagg J, Gologan O, et al
   Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
   BMC Cancer. 2019;19:68.
   PubMed     Text format     Abstract available
   
   

   
   Cancer

10. WINDON MJ, D'Souza G, Faraji F, Troy T, et al
    Priorities, concerns, and regret among patients with head and neck cancer.
    Cancer. 2019 Jan 15. doi: 10.1002/cncr.31920.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

11. GROSSBERG AJ, Vichaya EG, Christian DL, Molkentine JM, et al
    Tumor-Associated Fatigue in Cancer Patients Develops Independently of IL1 Signaling.
    Cancer Res. 2018;78:695-705.
    PubMed     Text format     Abstract available
    
    

    
    Clin Nucl Med

12. HOBERUCK S, Michler E, Seppelt D, Kotzerke J, et al
    Unexpected Bone Metastases in 99mTc-Pertechnetate Scan of Recurrent Goiter.
    Clin Nucl Med. 2018 Oct 8. doi: 10.1097/RLU.0000000000002302.
    PubMed     Text format     Abstract available
    
    
13. AVRAM AM, Rosculet N, Esfandiari NH, Gauger PG, et al
    Differentiated Thyroid Cancer Outcomes After Surgery and Activity-Adjusted 131I Theragnostics.
    Clin Nucl Med. 2018 Oct 27. doi: 10.1097/RLU.0000000000002321.
    PubMed     Text format     Abstract available
    
    

    
    Dis Esophagus

14. ZHANG R, Li Y, Liu S, Liu X, et al
    FA01.03: USE OF 'NON-TUBE NO FASTING' ERAS PROTOCOL IN PATIENTS AFTER MIE WITH LI'S ANASTOMOSIS: OUTCOMES IN THE FIRST 113 PATIENTS PERFORMED BY A SURGEON AFTER TRAINING COURSE.
    Dis Esophagus. 2018;31:1-2.
    PubMed     Text format     Abstract available
    
    
15. FRANSEN L, Berkelmans G, Asti E, Van Berge Henegouwen M, et al
    FA01.02: THE EFFECT OF POSTOPERATIVE COMPLICATIONS AFTER MIE ON LONG-TERM SURVIVAL: A RETROSPECTIVE, MULTI-CENTER COHORT STUDY.
    Dis Esophagus. 2018;31:1.
    PubMed     Text format     Abstract available
    
    
16. KWAN KIT CHAN D, Siu Yin Chan F, King Hung Tong D, Yu Hong Wong I, et al
    FA01.01: MINIMALLY INVASIVE APPROACH RESULTS IN BETTER OUTCOME COMPARED TO OPEN ESOPHAGECTOMY-A PROPENSITY SCORE MATCHED ANALYSIS.
    Dis Esophagus. 2018;31:1.
    PubMed     Text format     Abstract available
    
    
17. KANEOKA A, Yang S, Inokuchi H, Ueha R, et al
    Presentation of oropharyngeal dysphagia and rehabilitative intervention following esophagectomy: a systematic review.
    Dis Esophagus. 2018;31.
    PubMed     Text format     Abstract available
    
    

    
    Head Neck

18. SINGER S, Amdal CD, Hammerlid E, Tomaszewska IM, et al
    International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV.
    Head Neck. 2019 Jan 12. doi: 10.1002/hed.25609.
    PubMed     Text format     Abstract available
    
    
19. CHAN JW, Yeh I, El-Sayed IH, Algazi AP, et al
    Ultraviolet light-related DNA damage mutation signature distinguishes cutaneous from mucosal or other origin for head and neck squamous cell carcinoma of unknown primary site.
    Head Neck. 2019 Jan 11. doi: 10.1002/hed.25613.
    PubMed     Text format     Abstract available
    
    
20. BECKHAM TH, Leeman J, Jillian Tsai C, Riaz N, et al
    Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: A series of 9 cases and review of the literature.
    Head Neck. 2019 Jan 11. doi: 10.1002/hed.25577.
    PubMed     Text format     Abstract available
    
    
21. LEE JW, Ban MJ, Park JH, Lee SM, et al
    Visceral adipose tissue volume and CT-attenuation as prognostic factors in patients with head and neck cancer.
    Head Neck. 2019 Jan 12. doi: 10.1002/hed.25605.
    PubMed     Text format     Abstract available
    
    

    
    Histopathology

22. PUETZ K, Bollschweiler E, Semrau R, Monig SP, et al
    Neoadjuvant chemoradiation for patients with advanced esophageal cancer- Which response grading system best impacts prognostic discrimination?
    Histopathology. 2019 Jan 12. doi: 10.1111/his.13811.
    PubMed     Text format     Abstract available
    
    

    
    Int J Cancer

23. DUDDING T, Johansson M, Thomas SJ, Brennan P, et al
    Assessing the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal cancer using Mendelian randomization.
    Int J Cancer. 2018;143:1029-1036.
    PubMed     Text format     Abstract available
    
    

    
    Laryngoscope

24. NILSEN ML, Mady LJ, Hodges J, Wasserman-Wincko T, et al
    Burden of treatment: Reported outcomes in a head and neck cancer survivorship clinic.
    Laryngoscope. 2019 Jan 15. doi: 10.1002/lary.27801.
    PubMed     Text format     Abstract available
    
    
25. DU E, Mazul AL, Farquhar D, Brennan P, et al
    Long-term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status.
    Laryngoscope. 2019 Jan 13. doi: 10.1002/lary.27807.
    PubMed     Text format     Abstract available
    
    
26. UNSAL AA, Booth JR, Rossi NA, Byrd JK, et al
    Basaloid nasopharyngeal carcinoma: A population-based analysis of a rare tumor.
    Laryngoscope. 2019 Jan 10. doi: 10.1002/lary.27788.
    PubMed     Text format     Abstract available
    
    
27. TORABI SJ, Cheraghlou S, Kasle DA, Savoca EL, et al
    Nonsquamous cell laryngeal cancers: Incidence, demographics, care patterns, and effect of surgery.
    Laryngoscope. 2019 Jan 10. doi: 10.1002/lary.27785.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: